The directors are confident that they have delivered a suitable candidate to Roche through the discovery of "new cell penetrating peptides".
How much will it cost Roche to progress the deal? According to the September 2010 presentation, Roche can exercise its option through the payment of "a pre-negotiated 8 figure" amount.
Writing down all the zeros in a straight line makes that a minimum $10m sign on deal. Undoubtedly, $10m is an inexpensive investment for access to an intracellular phylomer transporter in the next major frontier for drug development.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.39 |
Change
0.030(2.21%) |
Mkt cap ! $810.7M | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.39 | $1.33 | $103.4K | 75.90K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2600 | $1.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 14999 | 1 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |